Rule 8 - Cambridge Antibody

RNS Number:9254G
Fidelity International Ltd
31 January 2003


                                         Date of Disclosure JANUARY 31, 2003

                    DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 
                       OF THE CITY CODE ON TAKEOVERS AND MERGERS

Date of dealing     JANUARY 30, 2003

Dealing in    CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC       (name of company)

1)  Class of securities (eg ordinary shares)  ORDINARY SHARES

2)  Amount bought                Amount sold             Price per unit

                                 107,153                 7.8477462$/SHARE


3)  Resultant total of the same class owned or controlled 
    (and percentage of class)     2,871,150               (7.90%)


4) Party making disclosure  FMR CORP. AND FIDELITY INTERNATIONAL LIMITED


5)  EITHER (a) Name of purchaser/vendor (Note 1)    
    OR     (b) if dealing for discretionary client(s), name of fund 
               management organisation    
               FMR CORP. AND/OR ONE OR MORE OF ITS DIRECT AND INDIRECT 
               SUBSIDIARIES, FMTC AND/OR ONE OR MORE OF ITS DIRECT AND INDIRECT 
               SUBSIDIARIES, AND FIDELITY INTERNATIONAL LIMITED AND/OR ONE OR 
               MORE OF ITS DIRECT AND INDIRECT SUBSIDIARIES.

6)  Reason for disclosure (Note 2)                                     
    (a) associate of (i) offeror (Note 3)                       YES
                    (ii) offeree company                        NO


Specify which category or categories of associate (1-8 overleaf)  DEFINITION 6

If category (8), explain

     (b)  Rule 8.3 (ie disclosure because of ownership or control of 1% 
          or more of the class of relevant securities dealt in)  YES

Signed, for and on behalf of the party named in (4) above  

(Also print name of signatory)  JULIE FINOCCHIO

Telephone and extension number  ELEANOR CHEMLEN   (1) 617 563-1416


Note 1.  Specify owner, not nominee or vehicle company.  If relevant, also 
         identify controller of owner, eg where an owner normally acts on 
         instructions of a controller

Note 2.  Disclosure might be made for more than one reason; if so, state all 
         reasons.

Note 3.  Specify which offeror if there is more than one.

Note 4.  When an arrangement exists with any offeror, with the offeree company 
         or which an associate of any offeror or of the offeree company 
         in relation to relevant securities, details of such arrangement must 
         be disclosed, as required by Note 6 on Rule 8

Note 5.  It may be necessary, particularly when disclosing derivative 
         transactions, to append a sheet to this disclosure form so that
         relevant information can be given.

Note 6.  In the case of an average price bargain, each underlying trade 
         should be disclosed.

For full details of disclosure requirements, see Rule 8 of the Code.  If in 
doubt, contact the Panel on Takeovers and Mergers, Tel No: 020 7382 9026


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DCCSDDFMFSDSEEF